Evidence map›Paper›PMID 35246801›Full record

ArticleDigestive diseases and sciences2022

Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study.

Lucas Guillo, Aurélien Amiot, Mélanie Serrero, Romain Altwegg, Xavier Roblin, Calina Atanasiu, Anthony Buisson, Catherine Le Berre, Catherine Reenaers, Jean-Marc Gornet and 13 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Clots in colitis: Thromboembolism and beyond.World journal of clinical cases · 2025
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 4 countries.

Lucas GuilloDepartment of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Chemin des Bourrely, 13015, Marseille, France. lucas.guillo690@gmail.com.ORCID 0000-0001-9024-8541
Aurélien AmiotDepartment of Gastroenterology, Groupe Hospitalier Henri Mondor-Albert Chennevier, APHP, EC2M3-EA7375, University of Paris Est Créteil, Créteil, France.
Mélanie SerreroDepartment of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Chemin des Bourrely, 13015, Marseille, France.
Romain AltweggDepartment of Gastroenterology, Saint-Eloi Hospital, University Hospital of Montpellier, Montpellier, France.
Xavier RoblinDepartment of Gastroenterology, Saint-Etienne University Hospital, Saint-Étienne, France.
Calina AtanasiuDepartment of Gastroenterology, AP-HP, Hôpital Saint-Joseph, Paris, France.
Anthony BuissonUniversité Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.
Catherine Le BerreDepartment of Gastroenterology, Institut des Maladies de L'Appareil Digestif (IMAD), CIC Inserm 1413, Nantes University Hospital, Nantes, France.
Catherine ReenaersDepartment of Gastroenterology, University Hospital of Liège, Liège, Belgium.
Jean-Marc GornetAssistance Publique - Hôpitaux de Paris, Hôpital Saint Louis, Université de Paris, Paris, France.
David LaharieCHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive - Université de Bordeaux, 33000, Bordeaux, France.
Vered AbitbolDepartment of Gastroenterology, Paris Descartes University, Sorbonne Paris Cité, Cochin Hospital, APHP, Paris, France.
Amélie BironDepartment of Gastroenterology, Reims University Hospital, Reims, France.
Bénédicte CaronDepartment of Gastroenterology, Hautepierre Strasbourg University Hospital and INSERM U1113 IRFAC, University of Strasbourg, Strasbourg, France.
Stéphane NanceyDepartment of Gastroenterology and Inserm U1111-CIRI, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, France.
Antoine ChupinDepartment of Gastroenterology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris and Université Paris Saclay, Le Kremlin-Bicêtre, France.
Antoine BlainDepartment of Gastroenterology, Institut Mutualiste Montsouris, Paris, France.
Lucine VuittonDepartment of Gastroenterology, Besancon University Hospital, Besançon, France.
Ludovic CailloDepartment of Gastroenterology, University Hospital of Nimes, Nîmes, France.
Julien KirchgesnerDepartment of Gastroenterology, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Sorbonne Université, Paris, France.
Maria NachuryUniv, Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, 59000, Lille, France.
Laurent Peyrin-BirouletDepartment of Gastroenterology, Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
FOCUS Study Group
Inserm · FRAix-Marseille Université · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Hospitalier Universitaire de Nîmes · FRCentre Hospitalier Universitaire de Reims · FRCentre Hospitalier Universitaire de Saint-Étienne · FRDélégation Paris 5 · FRInstitute Mutualiste Montsouris · FRUniversité Claude Bernard Lyon 1 · FRUniversité de Bordeaux · FRUniversité Paris-Est Créteil · FRUniversité Paris-Saclay · FRUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsPatients with inflammatory bowel disease have an increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD). The study aims to determine the prevalence of CVD and VTE risk factors in a large population of patients with ulcerative colitis (UC).

methodsWe conducted a cross-sectional study in 33 French and Belgium referral centers. A questionnaire was developed to explore self-reported risk factors for VTE and CVD, based on the latest international guidelines, in consecutive patients with UC.

resultsA total of 1071 patients with UC were included. There were 539 women (50.3%), and the median age of patients was 44 years [32; 57]. The median disease duration was 10 years [6; 17]. In the cohort, 36.5% of patients reported no cardiovascular risk factor (CVRF) and 72% had ≤ 1 CVRF. Regarding cardiovascular risk markers (CVRM) 36.9% of patients reported no CVRM and 78% had ≤ 1 CVRM. Of the 1071 patients, 91.3% of patients reported no VTE strong risk factor and 96% had ≤ 1 VTE moderate risk factor.

conclusionThis is the first cohort specifically designed to assess both VTE and CVD risks in patients with UC. More than one third of patients with UC had no CVRF and around three quarters had ≤ 1 CVRF. In addition, more than nine out of ten patients had no VTE strong risk factor and ≤ 1 moderate risk factor. Physicians should be aware of these factors in their patients.

Indexed as

Cardiovascular DiseasesColitis, UlcerativeVenous ThromboembolismAdultCross-Sectional StudiesFemaleHumansPrevalenceRisk FactorsSelf ReportDisease progressionHeart disease risk factorsUlcerative colitisVenous thromboembolism

Identifiers

PMID35246801
OpenAlexW4214836649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.